RPL22 Blocking Peptide Summary
A peptide corresponding to amino acids from the C-terminal region of human RPL22. Accession #: NP_033105.
Source: Synthetic
Amino Acid Sequence: SKRYLKYLTKKYLKKNNLRDWLRVVANSKESYELRYFQINQDEEEEEDED
Synthetic
Blocking Peptide
RPL22
N/A
Applications/Dilutions
This is a synthetic peptide designed for use in combination with anti-Rpl22 Antibody NBP1-98446. It may block the above mentioned antibody from binding to its target protein in western blot and/or immunohistochemistry applications under proper experimental settings.
15 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Packaging, Storage & Formulations
Store at -20C. Avoid freeze-thaw cycles.
Lyophilized with sterile distilled water.
No Preservative
LYOPH
N/A
Add 100ul of sterile PBS. Final peptide concentration will be 1 mg/ml in PBS.
Notes
For longer periods of storage, aliquot and store at -20C. Avoid repeat freeze-thaw cycles.
Alternate Names for RPL22 Blocking Peptide
- EAPHBP15
- EBER-associated protein
- Epstein-Barr virus small RNA-associated protein
- Epstein-Barr-encoded RNA-associated protein
- HBP15/L22
- heparin-binding protein 15
- Heparin-binding protein HBp15
- ribosomal protein L22,60S ribosomal protein L22
Background
The function of this protein remains unknown.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.
product targets :　Protease_Inhibitor_Cocktail inhibitors